234 related articles for article (PubMed ID: 17139584)
1. [Oral antidiabetic therapy].
Schneider S; Pazdzierny G; Klein HH
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S264-7. PubMed ID: 17139584
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
3. [Triple oral therapy in type 2 diabetes].
Scheen AJ
Rev Med Suisse; 2005 Aug; 1(30):1942, 1944-6, 1948. PubMed ID: 16200937
[TBL] [Abstract][Full Text] [Related]
4. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
Bell DS
Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
[TBL] [Abstract][Full Text] [Related]
5. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
Malesker MA
Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
[TBL] [Abstract][Full Text] [Related]
6. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy.
Buse JB
Diabetes Care; 1999 Apr; 22 Suppl 3():C65-70. PubMed ID: 10189565
[No Abstract] [Full Text] [Related]
7. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
8. Oral antidiabetic combination therapy with sulphonylureas and metformin.
Haupt E; Knick B; Koschinsky T; Liebermeister H; Schneider J; Hirche H
Diabete Metab; 1991 May; 17(1 Pt 2):224-31. PubMed ID: 1936481
[TBL] [Abstract][Full Text] [Related]
9. [Development of body weight during antidiabetic treatment].
Hamann A
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S255-8. PubMed ID: 17139582
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
11. [Clinically important effects of oral antidiabetic drug interactions].
Drzewoski J; Kopff B
Pol Merkur Lekarski; 2000 Sep; 9(51):605-7. PubMed ID: 11126985
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
13. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
14. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
Sillars B; Davis WA; Hirsch IB; Davis TM
Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
[TBL] [Abstract][Full Text] [Related]
15. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
Fisman EZ; Tenenbaum A; Motro M; Adler Y
Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
[TBL] [Abstract][Full Text] [Related]
16. Metformin in noninsulin-dependent diabetes mellitus.
Lee AJ
Pharmacotherapy; 1996; 16(3):327-51. PubMed ID: 8726592
[TBL] [Abstract][Full Text] [Related]
17. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
18. Rational choice of oral antihyperglycaemic agents.
Chowdhury S; Sengupta N
J Indian Med Assoc; 2002 Mar; 100(3):174-5, 177. PubMed ID: 12408278
[TBL] [Abstract][Full Text] [Related]
19. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
20. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
